Source: British Heart Foundation
Follow this link for full text
Date of publication: March 2017
Publication type: Research
In a nutshell: Researchers have found a new target for drugs to prevent dangerous blood clots in the legs, thanks to our funding. The research found that mice with a defective receptor called CLEC-2 were protected from deep vein thrombosis.
The current treatments for deep vein thrombosis (DVT), which affects around 60,000 people in the UK every year, include anti-clotting drugs such as heparin and warfarin. These drugs are relatively effective but put patients at increased risk of dangerous bleeding. This is because as well as targeting the blood clot, they also affect haemostasis, the body’s natural response to blood vessel injury and bleeding. Imbalanced haemostasis can be dangerous, so patients have to be monitored carefully and hospitalised following bleeding injury.
Length of publication:
Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.
Acknowledgement: British Heart Foundation